An Update on Novel Pharmacotherapies for the Treatment of Neuroendocrine Tumors
International Journal of Molecular Sciences · 16.11.2025 · 26 (22) · 11095
DOI: 10.3390/ijms262211095 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 16.11.2025. Verfasst von Khalil Choucair und 4 weiteren Autor:innen. Beteiligte Einrichtung: Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, 4100 John R Street, Detroit, MI 48201, USA. Hauptthemen laut MEDLINE: Neuroendocrine Tumors, Antineoplastic Agents, Pancreatic Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 148 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, Asfar Azmi, NIH NCI.
Abstract (Originalsprache)
Neuroendocrine tumors (NETs) are heterogeneous neoplasms with different molecular characteristics and prognosis. Although slow-growing, NETs are often diagnosed at an advanced stage. The treatment choice depends on primary site, extent, grade, growth rate, somatostatin receptor status, functional status, performance status, and comorbidities. Precise knowledge of the biological and molecular features of NETs has led to the development of novel therapies. Therapeutic options include somatostatin analogs, multi-targeted tyrosine kinase inhibitors (e.g., sunitinib), or mammalian targets of rapamycin (mTOR) inhibitors (e.g., everolimus), telotristat ethyl, chemotherapy, and peptide-receptor radionuclide therapy. Pivotal studies that led to approval, treatment-related adverse events, and safety concerns, as demonstrated in clinical trials and real-world clinical practice. Questions, such as the optimal timing, selection, and sequence of therapies, and biomarkers that predict response to the novel agents in an individual patient, remain to be answered. We propose a stepwise approach for the management of advanced Gastro-entero-pancreatic (GEP)-NETs that utilizes a multidisciplinary team of experts. Biomarkers may assist in both the diagnosis and post-treatment follow-up in patients with GEP-NETs. The next decade of research on GEP-NETs is promising and should provide new insights into the molecular underpinnings of this disease, therapy selection, and the sequencing of the available therapies, along with the potential role of AL in NET pharmacotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, 4100 John R Street, Detroit, MI 48201, USA.
ORCID-Profile: Khalil Choucair, Roupen Odabashian, Asfar Sohail Azmi, Muhammad Wasif Saif
Förderung
- NCI NIH HHS
- Asfar Azmi
- NIH NCI
Zitieren
APA
Choucair, K., Odabashian, R., Reddy, S. N., Azmi, A. S., & Saif, M. W. (2025). An Update on Novel Pharmacotherapies for the Treatment of Neuroendocrine Tumors. International Journal of Molecular Sciences, 26(22), 11095. https://doi.org/10.3390/ijms262211095
Vancouver
Choucair K, Odabashian R, Reddy SN, Azmi AS, Saif MW. An Update on Novel Pharmacotherapies for the Treatment of Neuroendocrine Tumors. International Journal of Molecular Sciences. 2025;26(22):11095. doi:10.3390/ijms262211095
BibTeX
@article{Choucair2025,
author = {Choucair, Khalil and Odabashian, Roupen and Reddy, Sushmita Nanja and Azmi, Asfar Sohail and Saif, Muhammad Wasif},
title = {An Update on Novel Pharmacotherapies for the Treatment of Neuroendocrine Tumors},
journal = {International Journal of Molecular Sciences},
year = {2025},
volume = {26},
number = {22},
pages = {11095},
doi = {10.3390/ijms262211095}
}
EUVIMED